John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Incorporation Of Venetoclax Into AML Treatment. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
Incorporation Of Venetoclax Into AML Treatment
